Movalis (Meloxicam)

Meloxicam works by selectively inhibiting the cyclooxygenase‑2 (COX‑2) enzyme, which is responsible for producing prostaglandins that mediate inflammation, pain, and fever. By reducing prostaglandin synthesis, meloxicam diminishes the inflammatory response and alleviates associated discomfort.

The appropriate dose of Movalis is determined by the prescribing healthcare professional based on the individual’s medical condition, age, renal and hepatic function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of meloxicam in pregnancy is not well established, and it is generally avoided, especially in the third trimester due to potential fetal risks. Limited data are available for breastfeeding; therefore, a risk‑benefit assessment by a healthcare provider is essential before use.

To order Movalis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Movalis (meloxicam) offers a relatively selective COX‑2 inhibition compared with non‑selective NSAIDs like ibuprofen or naproxen, which may result in a lower incidence of gastrointestinal side effects. However, cardiovascular and renal risks remain and should be weighed against alternative agents on an individual basis.

Store Movalis at ambient temperature, preferably below 25 °C. Keep the tablets in their original packaging, protect them from moisture, heat, and direct sunlight to maintain product stability throughout its shelf life.

Movalis is taken orally, usually with a full glass of water. It may be taken with or without food, but taking it with food can help reduce possible stomach upset. Patients should swallow the tablet whole and not crush or chew it.

Serious risks include gastrointestinal ulceration or bleeding, cardiovascular events such as heart attack or stroke, severe skin reactions (e.g., Stevens‑Johnson syndrome), liver injury, renal impairment, and anaphylaxis. Patients should seek immediate medical attention if they experience symptoms like severe abdominal pain, chest pain, sudden swelling, or rash.

Movalis should be avoided in individuals with known hypersensitivity to meloxicam or other NSAIDs, those with active gastrointestinal ulcers, severe heart failure, uncontrolled hypertension, late‑stage pregnancy, and patients with significant renal or hepatic impairment unless specifically directed by a physician.